🚨Episode 2 of the @Uromigos Year in Review is now available. Silke Gillessen joins Brian Rini and Tom Powles to review prostrate and cancer updates for 2025. Listen now for the details.   🎙️ GU Oncology Now: https://t.co/FwXQQZkZNm 🍎 Apple Podcasts: https://t.co/FwXQQZkZNm

1/3 Assessing MRD with informed ctDNA analysis is gaining traction in operable bladder cancer and is now established as not just a prognostic tool but also predictive of outcome with atezolizumab after surgery in ctDNA positives. https://t.co/MBdRmaG1hB

Send money across the room or across the world in an instant for free – then spend at over 130 million merchants worldwide while earning up to 5% back in free crypto on every purchase.

After cystectomy for muscle-invasive bladder cancer, many patients are at risk for recurrence. Research findings from the IMvigor011 phase 3 trial are summarized in a new Quick Take video. https://t.co/NhbWDsBXm9

3/3 Does this data help tell us whether we can stop adjuvant perioperative IO regimens after surgery? Sadly not. Stopping IO after short periods based on ctDNA status is unproven. As IO moves earlier IM011 data potentially becomes less relevant. @OncoAlert @PGrivasMDPhD @NEJM

2/3 The negatives (~50%) who remain negative have a great outcome (>95% OS) . Also the ctDNA -ves didn’t benefit from IO in CM274 and IM010 (HRs~1). These patients can be spared the significant risk of life changing toxicity. @OncoAlert @NEJM

1400% growth price target: (that’s 15× from $1.23). Not a promise — just the math of a re-rate - analysts target NOTHING TO SEE HERE!!! Just NASDAQ: $MYNZ quietly stacking cancer-screening catalysts: Pancreatic (blood test feasibility): reported 100% sensitivity / 95%

1/3 Assessing MRD with informed ctDNA analysis is gaining traction in operable bladder cancer and is now established as not just a prognostic tool but also predictive of outcome with atezolizumab after surgery in ctDNA positives. https://t.co/MBdRmaG1hB

シスプラチン適格性に関わらずMIBCに周術期化学療法を使う時代が来ます。IO-based? EV-based? むしろEVP-basedか？そして、NAC or Adjではなく、perioperative chemo (POC?)が定着するか？

KEYNOTE-B15 / EV-304 is a huge win for patients 🟢 The shift from cisplatin-based chemo to peri-op EV+pembro opens critical new ❓❓❓ • What’s the true contribution of adjuvant therapy? (~65% received it in KEYNOTE-905) • How should we treat ctDNA-negative pts? MODERN will

Just out 👉 "Does adjuvant ICI have a future in operable MIBC?" @EurUrolFocus The paradigm is shifting from unselected adjuvant therapy toward ctDNA-guided and perioperative strategies. Results from EV-304 move this field forward. @OncoAlert @urotoday https://t.co/ZUZ8pThec9

Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer https://t.co/UEV0JiM1iC

EV/Pembro has another positive trial (EFS & OS) in MIBC. This time vs chemo/surgery rather than just surgery (KN905 (pCR 57%)). Will these results be better than NIAGARA (chemo/durva OS-0.75). In M1 disease EVP>chemo/IO, but let’s see in MIBC. https://t.co/UEV0JiMz8a

The OncoAlert 🚨Spotlight is Back This week @scocmem talks to us about her new article "Toward biomarker-driven therapies for urothelial carcinoma" written with co authors @b_szabados & @tompowles1 and out on nature reviews clinical oncology Download the article here:

New AUC3 2025 consensus (51 international experts) addresses the rapidly evolving landscape of RCC and UC. 📌Strong support for adjuvant pembro in higher-risk RCC 📌EV+pembro frontline in mUC and platinum-based chemo in FGFR3/HER2- after PD @OncoAlert @montypal @DrChoueiri

🎙️ A candid conversation with @tompowles1—two clinicians reality-checking each other—on ESMO’s guidance for #LLMs in oncology. We focus not just on what’s possible, but how AI should be implemented, and where the limits lie. 🙏 to @myESMO and all co-authors! @jnkath @Prof_Koopman

Renal Cell Carcinoma Year in Review podcast now available! https://t.co/TcBZHfBKk1

🌟 new FDA approval for PARPi in metastatic castrate-sensitive #prostatecancer w/ BRCA2 today! 🚹nira + abi in pts vs abi in #BRCA2 mCSPC 🌀met rPFS; but only 36% in control got PARPi at progression ❓OS immature, sequencing w/ pluvicto/chemo, long-term AEs: MDS/AML

Thank you to @myESMO & #ESMOImmuno25 for the opportunity to open the ADC session and discuss how these drugs are driving transformative change in cancer management. Honoured to share the stage with global experts across academia and industry @sciqst @LauBuisseret

While KIM-1 hold promise in RCC the lack of clear definitions of positivity means exploratory analysis is prone to uncertainty. Perhaps the most robust data @Annals_Oncology is with adjuvant atezo @VincentWenxinXu @DrChoueiri @OncoAlert @montypal @vincent

Is KIM-1 the new ctDNA in clear cell renal cancer?. @brian_rini at 15th Shanghai Oncology Conference thinks it might be. Some standardisation is needed before prospective trials. @OncoAlert

Big positive step for metastatic prostate cancer. Precision oncology in mCSPC should be global standard of care as it aids treatment sequencing. AMPLITUDE demonstrates a convincing PFS benefit for BRCA2 population without compromising QOL.